Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, which is in phase 1, a tetravalent therapeutic candidate targeting death-receptor 5 to treat unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head non-small cell lung cancer cell carcinoma, gastric or gastroesophageal junction adenocarcinoma, renal cell carcinoma, and urothelial cell carcinoma. Inhibrx Biosciences, Inc. was incorporated in 2024 and is based in La Jolla, California.…
Inhibrx Announces Updated Clinical Data for Ozekibart (INBRX-109) in Ewing Sarcoma
Inhibrx Biosciences (NASDAQ: INBX) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 109 employees.
The shares were at 68.97 USD on 20 November 2026, down 14.5% over 52 weeks. Its 52-week range is 57.30 USD to 155.29 USD: the price is 55.6% below the high and 20.4% above the low.
Its market capitalisation is 1.02B USD.
Its debt exceeds its cash by 81.97M USD, a debt-to-equity ratio of 13.39. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. 3 analysts cover the stock, with an average rating of Buy; their mean price target of 258.33 USD is 274.6% above the current price. The next earnings report is expected on 18 March 2027.